| Name | Title | Contact Details |
|---|
KCR is a clinical development solutions provider for the biotechnology, pharmaceutical, and medical device industries. We support clients with full-service clinical development capabilities across three main areas: Trial Execution, Consulting and Placement. KCR operates across four main regions: North America, Western Europe, Central Europe, and Eastern Europe, with a main operational hub located in Boston, MA. Our strategic hub locations, technical capabilities and solution offerings allow for the optimized delivery of trial execution strategies to develop life-changing therapies. KCR offers access to an estimated population of 1.1 Billion people.
Dauntless Pharmaceuticals, Inc is a San Diego, CA-based biopharmaceutical company. The traditional biotech company holds numerous assets at various stages of development, and its investors, management, labs, and staff collectively share interest in all company assets. In contrast, Dauntless uses a one-asset, one-company model.
Recursion is a clinical-stage biotechnology company combining experimental biology and automation with artificial intelligence in a massively parallel system to efficiently discover potential drugs for diverse indications, including genetic disease, inflammation, immunology, and infectious disease. Recursion applies causative perturbations to human cells to generate disease models and associated biological image data. Recursion`s rich, relatable database of more than a petabyte of biological images generated in-house on the company`s robotics platform enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics to radically improve lives. Recursion is headquartered in Salt Lake City.
Veritas Pharma Inc (trading symbol CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) is an early stage pharmaceutical company developing innovative cannabinoid prescription medicines to treat medical conditions such as pain, emesis (nausea/vomiting), glaucoma, and epilepsy. Using a ‘lean and mean’ approach to product development, the company aims to select candidate medicines using classical pharmacology techniques and then immediately evaluate them in the clinic to maximize both product value and shareholder return. Veritas’s scientists are an inter-disciplinary team that consists of chemists, pharmacologists, anesthetists, and clinical pharmacologists. Their focus is to use their knowledge to streamline the development of cannabis based treatments to capture considerable market share. Also through its wholly owned subsidiary, Sechelt Organic Marijuana Corp., has applied to Health Canada for a medical marijuana production and distribution license under the Marihuana for Medical Purposes Regulations (the “MMPR“).